Document zdaJ3M2p0q6VQQqpgZ4Q8Oxo0
Denka
Denk P'ftQffrarKe D vton
Request to Correct IRIS' 2010 Toxicological Review of Chloroprene
June 28,2017
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00001
DPE Presentation Agenda
introductions - Nao Kawamura, Vice President of Administration
Overview of Denka Performance Elastomer President and CEO Koki Tabuchi
Summary of basis for requesting correction Plant Safety, Health, and Environmental Manager Patrick Walsh, CIH
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00002
Denka
Denk P'fiofirance D v to n
Overview of Denka Performance Elastomer
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00003
Denka
Drflkri Wertet*ram. E'lvtonw '
Denka Performance Elastomer LLC
Formed to purchase Neoprene business from DuPont American entity with two parent companies from Japan
Denka Company Limited
70% Ownership
o Leading Chemical Co in Japan o 100 year history o Elastomers, Performance Plastics, Inorganic Materials, Electronics, Life Science o 6 Domestic Plants, 9 Overseas including Pontchartrain
Mitsui & Co. - 30% Ownership
Always strive for excellence in safety and environmental stewardship
Will work to maintain place as integral member of the community and a good neighbor
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00004
SITE DEMOGRAPHICS & STATISTICS
NEOPRENE
TOTAL EMPLOYEES
249
RIVER PARISH RESIDENTS 77%
AVERAGE SERVICE YEARS 19
ANNUAL PAYROLL
RES. CONTRACTORS
125
APPROXIMATE PAYROLL $8.1MM
TAXES (STATE & LOCAL)
Jif \^
VALUE OF PURCHASES
$76.5MM
Third largest private employer in S t John Parish
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED_002061_00270547-00005
DPE to URE
11/1/15: DPE takes ownership of the only Neoprene plant in North America after purchase from DuPont
12/17/15: EPA released National Air Toxics Assessment - study states that emissions from plant cause highest off-site cancer risk for any source in the country
The NATA risk calculations are based on facility emissions and on an erroneous and ultrahigh Unit Risk Estimate from IRIS' 2010 Review
The 2010 IRIS Toxicological Review of Chloroprene established an overly stringent inhalation Unit Risk Estimate (URE) or Inhalation Unit Risk (IUR) of 5 x 10 4/ug/m3for a 70-year, lifetime exposure.
URE has been applied to calculate a 100-in-a-million cancer risk with annual average chloroprene concentrations of 0.2 ug/m3
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00006
Denka
Denk P'ftQffrarKe D vton
Summary of DPE's Request for Correction
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00007
Request for Correction - Summary of Bases
Brings study in line with recommendations from NAS/NRC
Toxicological evidence
Epidemiological evidence IUR derivation corrections
PBPK modeling results
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00008
NAS/NRC Recommendations
NRC has issued guidance on IRIS process in 2011 and 2014
Better transparency and rigor--some portions of 2010 Review cannot be reconstructed
Better evaluation of weight-of-evidence--certain weaker studies in 2010 Review given higher priority
Congress directed, and EPA agreed, to adopt the NRC recommendations
2010 Review published before these guidelines issued--updating the Review would bring the study in line with those recommendations
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00009
Toxicological Evidence - 1
Too much weight was given to the most sensitive species with inconsistent results across species
Study identified unique sensitivity in female mice this became a cornerstone of the IRIS Review
Did not attempt to account for important pharmacokinetic differences between mice and humans
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00010
Toxicological Evidence - 2
Mode-of-action (MOA) in 2010 Review needs to be updated
2010 Review hypothesizes a mutagenic MOA due to structural similarities with vinyl chloride and 1,3-butadiene
Published data does not support this---even NTP study states that chloroprene was not mutagenic in any of their tests
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
Denka
Denk P'ftQffrarKe D vtonw
ED 002061 00270547-00011
Epidemiological Evidence- 1
Too much weight applied to poor quality epidemiological studies, and not enough to the most high quality study
Most robust study (Marsh, et al. 2007) treated the same as less rigorous Russian, Armenian, and Chinese studies
Marsh study concluded that there is no link between occupational exposure to chloroprene and cancer mortality of any type
2010 Review disregarded Marsh study conclusion and focused on statistically insignificant increase in liver cancers observed in three subgroups because comparison group exhibited fewer cancers than expected
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00012
Epidemiological Evidence- 2
Rank
53
County
I
Annual Incidence Rate(+) over rate period - cases per
100,000
Average Annual Count over rate period
BW M H1
Rate Period
Recent Trend
Recent 5-
Year Trend
(*> m
Incidence Rates
'
lARCi*), 1999: "There is inadequate evidence in humans for the carcinogenicity of chloroprene."
^International Agency for Research on Cancer
http://statcancerprofi!es,cancer,Qov/inddencerates/index,php?statei............................ W lEtrace-.-QO&sex--GEtage ^O&ivpe-ncd&sortVaraheNaire-raie&sortOrder-defaulWresuits
tips //nn <:>pra ph s. rc,fr/E MG/fvlonog. hs/vol 71/nn 7 -9 pd
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00013
Denka
Offrit*Perte*trr Dv^oo
O verly Conservative Derivation of iu r
2010 Review interpreted the animal studies incorrectly
Treated each tumor as unique event, causing animals with multiple tumors to be counted twice in the risk analysis
Treated lung tumors as systemic rather than portal-of-entry effects
2010 Review assumed that IUR for female mice applies to human exposure
Applied age-dependent adjustment factor without sufficient evidence to support the incorrect mutagenic MOA
Rounding intermediate results multiple times in the same calculation skews final result
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00014
EPA s Chloroprene URE Should Be mm jt J
I 1
g% mm mm 1
I 1 p%
Consistent with Similar Compounds
Chemical
IARC EPA Carcinogenicity
Group
Assessment
URE
IARC Classifications:
1
Known Carcinogen
2B
2A
Probable Carcinogen
3
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
Possible Carcinogen Not Carcinogenic
ED 002061 00270547-00015
2010 Review Did Not Use PBPK Model
Presented with the evidence, EPA should have used a physiologically-based pharmacokinetic (PBPK) model to extrapolate mouse toxicology data to humans
Although a validated PBPK model (Himmelstein, 2004) was available at the time of the 2010 Review, EPA declined to use it
Since 2010, 3 separate studies have validated the Himmelstein model
2010 Review even states: "Ideally, a PBPK model...would decrease some of the quantitative uncertainty in interspecies extrapolation..." (p. 141)
Failure to use PBPK resulted in overly conservative IUR
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00016
Chloroprene is not "likely...carcinogenic"
2010 Review states that IRIS determined chloroprene's carcinogenicity based on the following criteria:
1. NTP study finding early appearance of tumors 2. Elevated liver cancer risk from occupational exposure 3. Suggestive evidence of increased lung cancer risk from
occupational exposure 4. Proposed mutagenic mode of action 5. Structural similarities to known carcinogens 1,3-butadiene
and vinyl chloride
RE's report shows that only 2 of these remain true
Chloroprene carcinogenicity should be downgraded to "suggestive to be carcinogenic in humans"
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00017
Ramboll Environ (RE) used NTP data with a PBPK model to derive a more scientifically grounded IUR Applied standard EPA methodology Used conservative assumptions where appropriate
Results are consistent with other structurally similar chemicals
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00018
Denka
D r'll Peno-inficr FI tome
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00019
Conclusions
IRIS' 2010 Toxicological Review of Chloroprene contains numerous deviations from accepted scientific practice
The RFC shows that current emissions of chloroprene are well within acceptable cancer risk calculations. Installation of the RTO and other AOC-required emission reduction projects must achieve 85% emissions reduction
The 2010 Review needs to be updated
Thank you
Sierra Club v. EPA 18cv3472 NDCA
Tier 3/4
ED 002061 00270547-00020